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Abstract
Background and objectives: International Normalized Ratio (INR) is a world-wide routinely used factor in the
monitoring of oral anticoagulation treatment (OAT). However, it was reported that other factors, e. g. factor II,
may even better reflect therapeutic efficacy of OAT and, therefore, may be potentialy useful for OAT monitoring.
The primary purpose of this study was to characterize the associations of INR with other vitamin K-dependent
plasma proteins in a heterogenous group of individuals, including healthy donors, patients on OAT and patients
not receiving OAT. The study aimed also at establishing the influence of co-morbid conditions (incl. accompanying
diseases) and co-medications (incl. different intensity of OAT) on INR.
Design and Methods: Two hundred and three subjects were involved in the study. Of these, 35 were normal
healthy donors (group I), 73 were patients on medication different than OAT (group II) and 95 were patients on
stable oral anticoagulant (acenocoumarol) therapy lasting for at least half a year prior to the study. The values of
INR and activated partial thromboplastin time (APTT) ratio, as well as activities of FII, FVII, FX, protein C, and
concentration of prothrombin F1+2 fragments and fibrinogen were obtained for all subjects. In statistical
evaluation, the uni- and multivariate analyses were employed and the regression equations describing the obtained
associations were estimated.
Results: Of the studied parameters, three (factors II, VII and X) appeared as very strong modulators of INR,
protein C and prothrombin fragments F1+2 had moderate influence, whereas both APTT ratio and fibrinogen had
no significant impact on INR variability. Due to collinearity and low tolerance of independent variables included
in the multiple regression models, we routinely employed a ridge multiple regression model which compromises
the minimal number of independent variables with the maximal overall determination coefficient. The best-fitted
two-component model included FII and FVII activities and explained 90% of INR variability (compared to 93% in
the 5-component model including all vitamin K-dependent proteins). Neither the presence of accompanying
diseases nor the use of OAT nor any other medication (acetylsalicylic acid, statins, steroids, thyroxin) biased
significantly these associations.
Conclusion: Among various vitamin K-dependent plasma proteins, the coagulation factors II, VII and X showed
the most significant associations with INR. Of these variables, the two-component model, including factors II and
VII, deserves special attention, as it largely explains the overall variability observed in INR estimates. The statistical
power of this model is validated on virtue of the estimation that the revealed associations are rather universal
and remain essentially unbiased by other compounding variables, including clinical status and medical treatment.
Further, much broader population studies are needed to verify clinical usefulness of methods alternate or
compounding to INR monitoring of OAT.
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Introduction
Oral anticoagulation (OAC) is a vital therapy for many
patients, e.g. suffering from tromboembolic events, atrial
fibrillation and after heart valves replacement [1,2]. It has
been well established that the incidence of complications
due to haemorrhage or thromboembolism in these
patients depends on the ability to maintain the level of
anticoagulation within therapeutic ranges. Due to indi-
vidual response to OAC, dose adjustment according to
regular monitoring, is necessary. Amongst a huge variety
of coagulation-related parameters, the prothrombin time
(PT) is of special interest since it directly reflects the rate
of thrombin generation [3]. Numerous in vitro studies
have shown that the rate of thrombin generation is line-
arly related to the concentration of factor II (FII) in the
assay system, thus suggesting a key role of prothrombin
levels in the expression of antithrombotic activity of oral
anticoagulant treatment (OAT). It was reported recently
that FII levels may reflect the true in vivo degree of antico-
agulation better then International Normalized Ratio
(INR) values in both stable and early phase of anticoagu-
lation [4]. The problem of the possible usefulness of other
parameters of blood coagulation has also been occasion-
ally raised, however the evidence accumulated hitherto
seems conflicting [5-9]. Therefore, although INR is still
widely used in routine OAT monitoring, there is a contin-
uous search for other reliable markers of individual coag-
ulation/anticoagulation status under different clinical
conditions.
In this study we employed the calculus of multivariate
methods to characterize the associations of INR with
other vitamin K-dependent plasma clotting factors in a
heterogenous group of individuals, including healthy
donors, patients on OAT and patients not receiving OAT.
Despite this primary objective, our secondary aim was
also to determine whether the associations between INR
and other coagulation variables may be biased by the
influence of co-morbid conditions (including accompa-
nying diseases) and co-medications (including different
intensity of OAT).
Materials and method
Study subjects
After obtaining an informed consent, 203 subjects were
involved in the study. Of these, 35 were normal healthy
donors (group I) and 73 were suffering from different
medical conditions and therefore were on single or com-
pounding medication but were not the users of OAT
(group II). Group III consisted of 95 subjects on stable
and permanent oral anticoagulant therapy lasting for at
least half a year. A basic demographic information and
medical history was obtained by means of a short ques-
tionnaire. The study protocol was approved by the Ethical
Committee of Medical University of Lodz.
Clinical Laboratory Methods
Peripheral venous blood samples (4.5 ml) were collected
using a 21 gauge needle and Vacutainer System (Becton
Dickinson) tubes containing 0.105 M sodium citrate.
Once drawn, the samples were immediately tested in
those devices requiring whole blood according to the
manufacturer's instructions. The remaining portions of
blood were separated into blood cells and platelet poor
plasma (1500 × g, 15 min), and the latter was kept frozen
at -80°C until assayed as described below.
Coagulant activities of factor II, VII and X, as well as pro-
thrombin time (INR), activated partial thromboplastin
time (APTT) ratio; protein C activity and fibrinogen were
measured in processed plasma in one-stage assays on the
ACL 7000 analyzer (Instrumentation Laboratory, USA)
using commercially available reagents and immunode-
pleted plasmas (IL Test™ APTT-SP (liquid), IL Test™ PT-
Fibrinogen Recombinant, IL Test™ Factor Deficient
Plasma II, VII, X and IL Test™ Test Protein C, respectively,
Instrumentation Laboratory, Italy). For the measurements
of INR and the vitamin K-dependent coagulation factors
we used the same thromboplastin (Test PT-Fib.Recom-
binant™, Instrumentation Laboratory, USA, ISI = 0.99).
Calibration curves were obtained and given by manufac-
turer and confirmed by ourselves using dilutions of nor-
mal pooled plasma collected from 40–60 apparently
healthy subjects. The concentration of prothrombin F1+2
fragments was measured by a commercially available
ELISA kit: Enzygnost®  F 1+2 micro (Dade Behring,
Germany), using an ELISA reader (BioRad Benchmark 550
Microplate Reader).
Statistical analysis
Due to departures of distributions of raw measurements
from normality (according to the Shapiro-Wilk test), data
are given as median and 25–75 percentile range (Me, 25–
75%QR). The sets of data that showed asymmetric distri-
butions were transformed and analyzed with the relevant
parametric tests, as described in the 'Results' section.
The differences between groups of thus transformed data
were evaluated by one-way analysis of variance and
Tukey's test for multiple comparisons.
The associations between variables presented as raw data
were analyzed with Spearman rank correlation (R); for
those between transformed data we employed either Pear-
son's linear correlation or multiple regression analysis
and partial correlation. In the multivariate analysis of all
data we used finally the ridge regression model of multi-
ple regression (standard and stepwise approaches of mul-
tiple regression analysis).Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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The outlying observations were censored using residual
regression analysis and the typical tests for outliers
(Dixon's Q test, Grubbs' test) [10-12]. Data allocation to
dispersion ellipses was performed using a forward step-
wise discriminant analysis.
Clinical (accompanying diseases) and pharmacological
parameters (treatment) were ranked dichotomically based
on the presence or absence of a given character/treatment.
To calculate the optimal cut-off point (≤ x or x ≥) between
the subjects on OAT treatment and the remaining donors
and patients with the sensitivity/specificity weighting
ratio possibly closest to 1.0, we employed the ROC analy-
sis. To assess the agreement between the two methods we
used the statistical procedure reported by Bland and Alt-
man [13,14]. In this method the association between the
differences from the paired outcomes of the two com-
pared methods and the averaged outcomes for all the con-
cordant and discordant pairs of data were regarded as the
measure of compatibility of the data collected with the use
of either direct monitoring of INR (INRexperimental) or sta-
tistical evaluation of INR on virtue of the collected values
of other plasma coagulation parameters (INRpredicted).
The calculations were performed using the statistical soft-
ware: Statistica®PL for Windows version 5.5 (StatSoft, Inc.
2000) and StatsDirect® (StatsDirect Ltd. 2000).
Results
Demographic and clinical characteristics of the studied
subjects, as well as the use of the drugs of known influence
on the coagulation status (acetylsalicylic acid, statins, ster-
oids, thyroxin), are presented in Table 1. All patients in
group III received acenocoumarol (synthetic derivate of 3-
(α-acetonylbenzyl)-4-hydroxycoumarin, vitamin K antag-
onist that impairs the synthesis of active plasma coagula-
tion factors: II, VII, IX, X; Acenocoumarol®,Polfa-
Warszawa, Poland) as a standard medication (Me = 18
mg/6 days, 25–75%QR = 12–24 mg/6 days). Indications
for OAT in patients representing group III are listed in
Table 2.
In this study we expectedly found differences in all studied
parameters between representatives of the group III
(patients on OAT) and the remaining donors and
patients. No significant differences were revealed between
normal healthy donors (group I) and patients of the
group II, except for prothrombin F1+2 which was signifi-
cantly higher in group II compared to healthy donors.
Further, for all the analyzed parameters but fibrinogen
and APTT ratio the cut-off points discriminating between
users and non-users of OAT lie far beyond the 25–75
percentile ranges estimated for group III by ROC curve
analysis (Table 3).
Secondly, using a multiparametric discriminant function
analysis we showed all the groups were significantly sepa-
rated apart (Fig. 1) and the variables which mostly con-
tributed to a significant discrimination of the groups, with
a maintenance of a minimum tolerance of 0.5, were factor
X (partial Wilk's lambda = 0.812, p « 0.0001), protein C
(partial Wilk's lambda = 0.907, p < 0.0002), fibrinogen
(partial Wilk's lambda = 0.922, p  < 0.001) and pro-
thrombin F1+2 (partial Wilk's lambda = 0.939, p < 0.003).
The most precise a posteriori allocation of cases to the a pri-
ori  assigned groups was found for the OAT patients
(93%), whereas the least precise characterized the control
healthy donors (41%).
Third, the associations between raw data of INR and each
of the remaining tested variables were apparently
hyperbolic and characterized by very significant Spear-
man's rank correlation coefficients (Fig. 2 inserts and leg-
end). To cope with the requirements of data linearity for
multivariate parametric analyses, we verified various
mathematical transformations of raw data (logarithmic,
semilogarithmic, reciprocal, square root). Based on the
estimates of individual linear correlation coefficients and
Table 1: Demographic and clinical characteristics of the studied subjects
group I (n = 35) group II (n = 73) group III (n = 95)
gender males 11 25 19
females 24 48 76
age (years) mean 47.4 59.4 59.5
range 22–74 32–78 24–74
compounding medication (n) acetylsalicylic acid 7 33 4
statins 0 11 7
steroids 0 16 3
thyroxin 0 5 13Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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homogeneity of raw data distributions we chose the loga-
rithmic transformation of raw data (X' = log(X) and Y' =
log(Y)). Fig. 2 (right panels) shows the linear partial asso-
ciations between INR and other variables. Contrary to
rank correlation, we observed significant linear associa-
tions of INR with all variables but the APTT ratio and
fibrinogen (the latter not shown). Simple linear (Pearson's)
correlation coefficients between all the analyzed variables
are given in Table 4.
In general, to reason on which of independent variables
contributes mostly to the variability of INR, we employed
the analysis of multiple regression. The residual analysis
(including testing for normality, homoscedasticity, auto-
correlation, linearity and outlying observations) was
always employed as a routine prior to the appropriate
multiple regression analysis performed on log-trans-
formed data. In the standard classical model of multiple
regression we included one dependent variable (INR) and
all 7 independent variables: fibrinogen, APTT ratio, FII,
FVII, FX, protein C and prothrombin F1+2. The significant
regression coefficients were found only for five of these
variables, whereas neither fibrinogen nor APTT ratio con-
tributed significantly to the explaining of INR variability.
Due to the low tolerance values for all of thus included
significant variables (0.1–0.3), pointing to a considerable
collinearity of all independent variables in such a model,
we further employed the ridge model of a forward step-
wise multiple regression with a lambda = 0.1. By the
extension of such criteria we finally built up the regression
function including five significant independent variables:
FII, FVII, FX, protein C, prothrombin F1+2, altogether
explaining over 92% of INR variability and each having a
tolerance of at least 0.22 (Table 5). Then, we gradually
eradicated from the model the independent variables with
the lowest significance and Fremove  values to finally
approach a two-component model including only FII and
FVII (overall R2 = 0.903, tolerance = 0.378 for each, partial
correlation coefficients: rFII = -0.711, rFVII = -0.659, p  «
0.0001 for each).
Using the above algorithm we accomplished the follow-
ing regression equations – for the complete five-compo-
nent model:
[INR] = -0.136 * [FII] -0.211 * [FVII] -0.104 * [FX] -0.088
* [protein C] -0.048 * [prothrombin F1+2] + 1.133
and the other for the "eradicated" two-component model:
[INR] = -0.251 * [FII] -0.296 * [FVII] + 1.168,
where [INR] = log(INR), [FII] = log(FII activity), [FVII] =
log(FVII activity), [FX] = log(FX activity), [protein C] =
log(protein C activity), [prothrombin F1+2] = log(con-
centration of prothrombin fragment F1+2).
In summary, (i) three of the assayed clotting parameters
(factors II, VII and X) appeared as very strong modulators
of prothrombin time (INR), (ii) protein C and pro-
thrombin fragments F1+2 had moderate influence, (iii)
whereas both APTT ratio and fibrinogen had no signifi-
cant impact on INR variability.
It should be emphasized that regardless of the complexity
of the overall multiple regression model, comprising from
2 to 7 independent variables, the variability of INR was
largely explained by the variabilities of the included
independent variables (from 90.3% for the 2-component
model up to 92.9% for the models including 5–7 varia-
bles). Further, the dominance of the complex multiple
regression model (with 5 independent variables of signif-
icant contribution) over single variable models in explain-
ing the total variability of INR was from 3.6% for FII and
5% for either FVII or FX to over 25% for F1+2. This clearly
demonstrates that each of these most significant contrib-
utors (clotting factors II, VII or X) remained apparently
sufficient in explaining the vast portion of an overall INR
variability. Moreover, due to collinearity and low toler-
ance of independent variables included in the multiple
regression model, one should rather consider such a ridge
multiple regression model which compromises the
minimal number of independent variables with the max-
imal overall determination coefficient. If so, there is no
need to monitor a large variety of clotting-related param-
eters and rather to choose a few most discriminating vari-
ables. Our estimates show that such conditions are
generally substantiated in the multiple regression model
comprising FII and FVII that altogether explained over
90% of overall INR variability.
To verify such an assumption we made a comparison
between a standard method (monitoring of INR) and
other (alternate) methods (prediction of INR based on the
monitoring of selected clotting factors and/or coagula-
tion-related variables). We used the above mentioned
Table 2: Indications for OAT in patients representing group III 
(with more than one indication for a patient possible)
Indication for therapy % of patients
atrial fibrillation 14
venous thromboembolism 5
postmyocardial infarction 14
cerebrovascular disease 5
prosthetic heart valve 79
miscellaneous 2Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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regression equations (for the 2-component model or for
the 5-component model) to calculate the predicted INR
values and compared the latter with the experimental INR
evaluated using a standard laboratory procedure [13].
Despite a very significant linear correlation between
INRexperimental  and INRpredicted (Fig. 3), we were further
interested whether these two approaches may be inter-
changeably applied in diagnostic practice, i.e. whether
these methods produce comparable data. The differences
between INRexperimental and INRpredicted within the pairs of
data exceeded the range of doubled SDdifference only in
4.5% and 3% of cases for the 2-component model and the
5-component model, respectively, which points to a very
good compatibility between both methods used to moni-
tor INR (Fig. 4). The mean difference between the meth-
ods enables to extrapolate the results obtained with a
regression method (INRpredicted) to those predicted to be
read with the other one (INRexperimental), provided the dis-
persion of differences lies in a narrow confidence limit
around the mean difference in the sample (Fig. 4).
Considering the dispersion of the differences recorded
within the pairs of data (since the standard errors of lower
or upper limit are respectively 
= 0.00666 for the 2-component model and
 = 0.00594 for the 5-compo-
nent regression model, and assuming the normal distribu-
tions of the differences for the 2-component model
95%  = -0.1112 ± 0.1081 (-0.1248; -0.0976) and
95%  = 0.1051 ± 0.1081 (0.0915; 0.1187) and for
the 5-component model 95%  = -0.0987 ± 0.0965(-
0.1105;-0.0863) and  95%  = 0.0947 ± 0.0965
(0.0826; 0.1068)), we may conclude that the outcomes of
the 'experimental' method of the monitoring of INR are
likely to be by up to 100.1112 = 1.29 lower or by up to
100.1187 = 1.31 higher compared to the results obtained
with the use of the regression method including 2 inde-
pendent variables, and by up to 100.0987 = 1.26 lower or by
up to 100.0947  = 1.24 higher compared to the results
obtained with the use of the regression method including
5 independent variables. Overall, we conclude that it is
fully justified to state that both methods of the estimation
of INR as the hallmark of the overall plasma coagulation
capacity (INRexperimental  and INRpredicted) may be used
interchangeably.
Finally, we employed the above mentioned multiple
regression models to verify whether and how far the
assigned relationships may be affected by (1) medication
or co-medication and (2) co-morbid conditions. The first
group of variables included (a) the use of OAT and its
dosing, (b) the use of acetylsalicylic acid and dosing, (c)
use of other drugs grouped into four classes: statins, ster-
oids, thyroxin, (d) OAT as the excluded grouping variable.
The second group of variables concerned the presence of
other accompanying diseases and disorders, including
venous thromboembolism, ischaemic heart disease, myo-
cardial infarction, stroke, diabetes, hypertension, liver and
intestinal tract diseases including ulceration, thyroid dis-
eases, cancer, osteoporosis, uraemia and kidney diseases,
mastopathy, gynaecological disorders, allergy, and rheu-
matoid diseases.
Neither the use of OAT, nor acetylsalicylic acid nor any
other medications affected significantly the variability of
the observed experimental INR. Also, we did not observe
the statistically significant impact of any accompanying
disorders and diseases on INRexperimental.
Table 3: Laboratory parameters values
group I (n = 35) group II (n = 73) group III (n = 95) cut-off point
PT [sec] 11.3 (10.8–12.3) 10.8 (10.4–11.6) 24.0 a (20.4–29.4) 13.21 (0.979, 0.990)
INR 1.02 (0.98–1.11) 0.98 (0.92–1.04) 2.16 a (1.84–2.60) 1.20 (0.979, 0.990)
APTT ratio 1.01 (0.96–1.10) 0.98 (0.92–1.10) 1.17 a (1.08–1.33) 1.03 (0.870, 0.645)
Fibrinogen [g/l] 3.36 (2.85–3.83) 3.60 (3.19–4.09) 4.17 b (3.59–4.63) 4.13 (0.537, 0.815)
FII [%] 132 (117–142) 133 (122–145) 25 a (19–35) 83.0 (0.989, 0.971)
FVII [%] 125 (108–133) 135 (125–142) 47 a (32–64) 91.1 (0.946, 0.963)
FX [%] 108 (92–120) 104 (96–113) 15 a (11–20) 68.1 (1.0, 0.942)
protein C [%] 118 (103–138) 125 (110–137) 54 a (46–64) 91.0 (0.968, 0.935)
prothrombin F1+2 [ng/ml] 0.87 (0.57–1.26) 1.26 c (0.98–1.71) 0.27 a (0.19–0.40) 0.528 (0.840, 0.934)
Data represent median and 25–75 percentile range. Cut-off points between users (group III) and non-users of OAT (groups I and II) estimated by 
ROC curve analysis with an a priori weighing of sensitivity:specificity ratio equal 1.0; the post hoc sensitivity and specificity estimates given in 
parentheses. Significance of differences between groups estimated for normalized data by one-way ANOVA (p « 0.0001 for all variables) and 
Tukey's test for multiple comparisons: a p « 0.0001; b p < 0.0002; c p < 0.05.
SEM s n ds ds −+= 22
2 3 , (/ )
SEM s n ds ds −+= 22
2 3 , (/ )
CIds − 2
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Discussion
Several recent studies have focused on evaluating markers
of activation of the haemostatic system in terms of
thrombin generation, such as prothrombin fragment
F1+2, thrombin-antithrombin (TAT) complexes, or clot-
ting factors [4,9,15]. Normally, small amounts of these
proteins are found in bloodstream, and are considered
hallmarks of the ongoing thrombin generation occurring
at sites with exposed tissue factor [16]. Obviously, in situ-
ations with increased thrombin generation (e. g.,
thromboembolism, surgery) these parameters may be ele-
vated, while they become markedly suppressed during
anticoagulant therapy [8,17-19]. On the other hand, the
prothrombin time (PT) may be subject to various modu-
lators, like oral anticoagulants [20]. To avoid biases from
both system-derived (variations among coagulation
analyzers) and reagent-derived sources (different batches
of thromboplastins), the prothrombin time is more often
expressed in terms of the International Normalized Ratio
(INR) [3]. In the clinical settings, the monitoring of INR
as an aid tool for OAT is only sporadically accompanied
by the routine laboratory assessment of other
coagulation-related haemostatic parameters. The accom-
plished evidence remains inconsistent in linking various
coagulation factors' activities to the INR values. In this
Classification of donors and patients according to the multi- variate discriminant function analysis including studied coagu- lation parameters Figure 1
Classification of donors and patients according to the multi-
variate discriminant function analysis including studied coagu-
lation parameters. Dispersion ellipses (95%CI) are drawn 
based on the coordinates of two orthogonal discriminant 
functions (roots) estimated in the course of a stepwise for-
ward discriminant function analysis (overall Wilk's lambda = 
0.191, p « 0.0001), including five variables (factor X, protein 
C, prothrombin F1+2, fibrinogen and APTT ratio), each with 
a tolerance of at least 0.5. Analysis performed on log-trans-
formed data in three groups: healthy donors (group I) (● ), 
patients who were non-users of OAT (group II) () and 
OAT users (group III) (❍ ).
Relationships between INR and plasma clotting factors, pro- tein C and F1+2 prothrombin fragments in normal donors  and patients on OAT Figure 2
Relationships between INR and plasma clotting factors, pro-
tein C and F1+2 prothrombin fragments in normal donors 
and patients on OAT. Cases representing patients on OAT 
are marked as open circles (❍ ), those representing healthy 
donors or patients not receiving OAT are marked by closed 
circles (● ). For non-linear associations of raw data (left 
panel) correlation coefficients represent Spearman's non-lin-
ear correlation; for log transformed data correlation coeffi-
cients represent partial correlation (for the model including 
all variables); insignificant coefficients marked with an aster-
isk, for the remaining p « 0.0001; coefficients estimated for 
whole set of experimental data (n = 203). In both methods 
the lines were computer-fitted to the data using the quasi-
Newton algorithm.Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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study we intended to characterize the associations of INR
with the activities of some vitamin K-dependent plasma
proteins and thus to evaluate how far the monitoring of
INR might be extended by or 'enriched' with the monitor-
ing of other coagulation-derived variables.
To perform this study, and for the purpose of the analysis,
we have chosen selected clotting factors directly partici-
pating in subsequent steps of a coagulation pathway
dependent on tissue factor and factor VII, previously
referred to as extrinsic coagulation pathway. In addition,
we picked up two other factors either directly or indirectly
related to thrombin generation: protein C and pro-
thrombin fragment F1+2 [17]. Whereas the former is cru-
cial in haemostatic feedback mechanisms governing de
novo thrombin generation [21], the latter is claimed to be
less affected by various compounding variables than for
example TAT, and therefore it appears to reflect coagula-
bility more accurately [22]. To ensure that the estimated
associations are representative as much as possible, we
have deliberately enrolled into the study a large cohort of
people representing not only healthy donors, but also
those in whom co-morbid conditions and/or co-medica-
tion might be observed.
All the parameters selected to this study have already been
proven to be affected by OAT [23]. The vitamin K-depend-
ent coagulation factors VII and X, as well as inhibitor
protein C have been reported to show a highly significant
correlation with treatment intensity [4,17,24]. Therefore,
by the inclusion of a heterogenous study population
comprising both patients on OAT and healthy donors, as
well as varying group of patients without OAT (of whom
20% were on aspirin), we deliberately broadened up the
naturally existing variability of the studied parameters.
Overall, the prothrombin time (INR) was affected mostly
by three of the assayed clotting factors: FII, FVII and FX.
Protein C and prothrombin fragments F1+2 had moder-
ate influence, whereas no significant impact on INR vari-
ability has been revealed for either APTT ratio or
fibrinogen. As deduced from R2 values, each of assayed
Table 4: Simple linear correlation coefficients between investigated coagulation parameters
INR Fibrinogen APTT ratio Factor II Factor VII Factor X Protein C Prothrombin F1+2
Fibrinogen 0.320 0.203 -0.353 -0.298 -0.345 -0.275 -0.298
APTT ratio 0.627 0.203 -0.603 -0.630 -0.600 -0.606 -0.582
Factor II -0.955 -0.353 -0.603 0.891 0.939 0.878 0.835
Factor VII -0.941 -0.298 -0.630 0.891 0.874 0.862 0.771
Factor X -0.940 -0.345 -0.600 0.939 0.874 0.882 0.810
Protein C -0.883 -0.275 -0.606 0.878 0.862 0.882 0.751
F1+2 -0.828 -0.298 -0.582 0.835 0.771 0.810 0.751
The coefficients were estimated for log-transformed data in the cohort including all 203 cases enrolled to the study (donors and patients). All 
coefficients were significant with at least p < 0.05.
Table 5: Summary of a ridge multiple regression model for clotting parameters explaining the variability of INR as a dependent variable
independent variable R2 βs p βoverall p
Fibrinogen 0.095 0.315 ± 0.068 5.91*10-6 -0.002 ± 0.019 0.921
APTT ratio 0.396 0.631 ± 0.055 1.98*10-23 0.024 ± 0.023 0.301
Factor II 0.893 -0.944 ± 0.024 0 -0.277 ± 0.042 3.07*10-10
Factor VII 0.884 -0.919 ± 0.028 0 -0.310 ± 0.036 1.68*10-15
Factor X 0.874 -0.935 ± 0.025 0 -0.229 ± 0.040 3.98*10-8
Protein C 0.783 -0.886 ± 0.033 0 -0.083 ± 0.035 0.019
Prothrombin F1+2 0.671 -0.820 ± 0.041 0 -0.088 ± 0.030 0.004
Model estimated for log-transformed data in all variables with the accepted value of λ = 0.1. The values in the columns 2 and 4 of the table refer to 
the standardized regression coefficients (bi) in the individual regression models (βs ± SE [βs]) including the individual independent variables, or to the 
overall ridge multiple regression model (βoverall ± SE [βoverall]) comprising all examined independent variables. The values of the determination 
coefficients (R2) denote the individual contributions of any given variable (estimated in single variable regression models) in explaining the overall 
INR variability; for the overall multiple regression model the corrected overall R2 = 0.9289; both individual and overall R2 were significant with p at 
least 0.0001. For the model of a ridge multiple regression with INR as a dependent variable and comprising all the independent variables the partial 
correlation coefficients rp are given in fig. 2.Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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parameters explained a very significant part of INR varia-
bility (from 10% in the case of fibrinogen up to nearly
90% in the case of factor II), when analyzed in the single
variable regression models. Based on the values of partial
correlation coefficients, only 5 parameters (mainly factors
VII, II and X which explained up to 92–93% of INR varia-
bility) showed significant partial contributions to INR,
whereas the effects of both fibrinogen or APTT ratio
remained negligible. It clearly points that each of these
insignificant parameters bears a large portion of a 'hidden'
variability resulting probably from their associations with
other plasma coagulation-derived variables and not nec-
essarily with INR. It goes along with the results of
Jerkeman et al., who found the strongest associations with
PT in the case of factor X, protein C, factor VII, IX and pro-
tein S. Unfortunately, factor II was not covered by the
scope of that study [17]. These results correspond also
with those obtained recently by D'Angelo et al., who
found FII monitoring to be a good alternative for INR
monitoring, as the parameter reflecting more closely in
vivo  antithrombotic potential [4]. Similar type of
agreement analysis has been reported by Kumar et al.,
however, the authors claimed only 50–77% proportion of
variability of the INR explained by the activities of clotting
factors II, VII, IX and X [23]. Our estimates only partly cor-
respond to those reported by Weinstock et al., who inves-
tigated the group composed of 80 OAT patients on initial-
and long-term warfarin therapy and 40 healthy volun-
teers, and, using a univariate analysis, they concluded that
factor VII, and not prothrombin, may be the predominant
factor monitored by INR [9]. On the other hand, Lind et
al. pointed that plasma levels of the vitamin K-dependent
coagulation factors are not equal in long-term OAT
patients. Using a multivariate analysis they showed factor
II levels to be the least significant of the three clotting fac-
tors (II, VII, X) measured in the determining of the
international normalized ratio in plasma or whole blood
[8], which opposes our present findings. Considering
such a moderately consistent array of data, the question
may be raised why not all studies in this area reached the
same estimates concerning the contributions of factors II
and VII to INR. We suggest that the conflicting results with
other authors' findings may be due to different PT rea-
gents for INR, since different PT reagents have different
sensitivities to individual coagulation factors and
inhibitors.
Another problem which needs to be addressed here is why
FVII and FII activities, which were significantly lower in
patients on OAT, did not contribute significantly to the
Linear regression as a measure of association between the values of INRexperimental and INRpredicted for (a) two-component  model and (b) five-component model of multiple regression Figure 3
Linear regression as a measure of association between the values of INRexperimental and INRpredicted for (a) two-component 
model and (b) five-component model of multiple regression.Thrombosis Journal 2003, 1 http://www.thrombosisjournal.com/content/1/1/7
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discrimination of the three groups of subjects. To reason-
ably interpret such an inconsistence we have to remember
that the inclusion of any variables into the model of dis-
criminant function analysis is based on the compromise
between the largest contribution of a given variable to the
improvement of the model (given by the partial Wilk's
lambda) and non-collinearity of included variables (given
by tolerance). In our analysis, both FII and FVII were
highly redundant parameters, collinear with other param-
eters and characterized by low tolerance values (below
0.240). On the other hand, both FII and FVII showed
merely moderate contributions (partial lambda Wilks'
values close to 1), compared to other analyzed variables.
Therefore, despite their significant differences between
groups, these two parameters were not included in the
model as the best discriminating parameters.
It is worth emphasizing that the associations obtained by
us were still valid in both healthy subjects and patients
suffering from different diseases. Neither the use nor the
intensity of OAT, nor the use of acetylsalicylic acid nor of
any other medications biased significantly these associa-
tions. This finding appears especially worth mentioning,
since it implies that the revealed association is a more gen-
eralized phenomenon, not merely attributed to either
OAT patients on one hand, or to healthy individuals with
undisturbed haemostasis on the other. In our opinion
such a universality of the estimated relationship is chal-
lenging in looking forward to novel strategies of the mon-
itoring of an overall haemostatic capacity in health or
disease. On the other hand, however, we need to admit
that our estimates apply predominantly to acenocou-
marol since other anticoagulants have not been studied in
our present approach.
To date the INR was considered a solely used universal
measure of an overall coagulation blood capacity and
numerous studies have proved its excellent usefulness for
the monitoring of OAT. The evidence that such a useful-
ness exists for other haemostatic parameters is no so
profound. Our present study points to other parameters
characterizing the overall haemostatic capacity that might
Scatter plot of the differences between pairs of data collected with the use of either 'experimental' or 'statistical' method as a  measure of agreement between the compared methods for (a) the two-component model and (b) the five-component model  of multiple regression Figure 4
Scatter plot of the differences between pairs of data collected with the use of either 'experimental' or 'statistical' method as a 
measure of agreement between the compared methods for (a) the two-component model and (b) the five-component model of 
multiple regression The plot presents the dependence between the measurement error (the difference between the outcomes of 
two compared methods) and the estimated true INR (the mean of means for both methods, the best µ of the selected sample 
population). The mean differences for the 2-component regression model and the 5-component regression model were 
respectively -0.00304 ± 0.0541   and -0.00185 ± 0.0483  . (( / ) . ) SEM s n d == 2 0 00384 (( / ) . ) SEM s n d == 2 0 00343Publish with BioMed Central    and   every 
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be potentially employed either alternatively or in a con-
junction with INR for the monitoring of OAT. This obser-
vation is of particular value as there is a continuous search
for a reliable OAT monitoring in point-of-care setting.
Despite the observed lack of the impact of numerous
pharmacological (oral anticoagulant dose, compounding
medication) and clinical parameters (accompanying
disorders and diseases), which seems very intriguing, it
needs to be emphasized that our opinion presented in this
study is merely a statistical point of view. Moreover, given
that various thromboplastins may differ in their sensitivi-
ties to reduced activities of different vitamin K-dependent
clotting factors, it is important to note that outcomes
obtained with different reagents may not be statistically
equal. Therefore, further, much broader population stud-
ies are certainly needed to verify the observed associations
and to validate the potential usefulness of the coagulation
parameters as compounding or alternate to INR measures
of coagulation capacity in both healthy donors and OAT
treated patients.
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